Good day, and welcome to the 2025 Phathom Pharmaceuticals Annual Stockholders Meeting. I would now like to turn the meeting over to the Chairman and Phathom's Board of Directors, Michael Cola. Mr. Cola, please go ahead. Thank you. Good morning and welcome to the 2025 Annual Stockholders Meeting of Phathom Pharmaceuticals. Thank you for joining us today. As is our custom, we will conduct the business portion of our meeting first and answer questions at the end of the meeting. Any unanswered questions will be addressed on the Investor Relations section of our corporate website following the meeting. To help us conduct an orderly meeting, we ask that stockholders abide by the rules of conduct available through the link on the webcast screen. It is now shortly after 11:30 A.M. Eastern Time on June 3rd, and this meeting is officially called to order. In light of the virtual meeting format, the polls are now open, and stockholders can vote by clicking on the Vote Here button on the bottom of the webcast screen. Members of Phathom's Board of Directors are attending today's meeting through the webcast. Also attending through this webcast are members of Phathom's senior management team and a representative of Ernst & Young LLP, the company's registered public accountant. Now, it is my pleasure to introduce Phathom's Corporate Secretary, Bill Apria. Bill will act as Secretary of the Meeting and will discuss some procedural matters with you. Thank you, Mike. Please note this meeting is being recorded and will be available for replay at www.virtualstockholdermeeting.com/phat2025. Even though we are providing a replay, no one attending via the webcast is permitted to use any audio recording device. Finally, the company has appointed me as Inspector of Election. On May 27th, 2025, I took the oath of Inspector of Election. The agenda and the rules of conduct are posted with other meeting materials at the bottom of the webcast screen. The procedures we follow are simple and are designed to ensure we have a fair and orderly meeting. As Mike explained, the polls are open. Most of you have already voted by proxy, and the proxy votes have been tallied. If you want to vote now or change your vote, you can click on the Vote Here button on the bottom of the webcast screen. The polls will stay open until the conclusion of the review of the matters to be voted on. After the formal meeting has been adjourned, we will provide time for general questions. Only validated stockholders may ask questions in the designated field on the web portal. Your question will not be visible to other participants. Out of consideration for others, please limit yourself to one question. As I mentioned earlier, even though this meeting is being recorded, attendees are not permitted to use any audio recording device. This meeting is being held pursuant to proper notice. 69,648,287 shares of common stock were outstanding and entitled to vote at this meeting as of April 7th, 2025, the record date of this meeting set by the company's Board of Directors. Proxy votes representing a majority of those shares have been received. Therefore, a quorum is present, and the meeting should proceed. Thank you, Bill. We will now review the matters to be voted upon. Proposal one is the election of two Class III directors. The current board has nominated Heidi Kunz and James Topper for election as directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are duly elected and qualified. Proposal two is the ratification of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025. Proposal three is the say-on-pay proposal to approve the compensation of the named executive officers on a non-binding advisory basis. Proposal four is to approve the proposal for the frequency of future non-binding advisory votes on the compensation of the named executive officers. Now that we have reviewed the matters to be voted on at this meeting, the polls for the 2025 Phathom Pharmaceuticals Annual Stockholders Meeting are closed. Bill, do we have preliminary voting results? We do, Mike. The preliminary vote report shows that the nominees for election to the board have been duly elected. The ratification of Ernst & Young as the company's independent registered public accounting firm has received sufficient for votes to be approved. The compensation of the named executive officers has received sufficient for votes to be approved on a non-binding advisory basis, and the frequency of future non-binding advisory votes on the compensation of the named executive officers has received sufficient one-year votes to be approved on a non-binding advisory basis. We will be reporting the final votes in a Form 8-K to be filed within four business days. Thank you, Bill. Now, we would like to respond to stockholder questions. Please note only questions that are germane to the meeting will be addressed. Questions not addressed at today's meeting will be addressed on the Investor Relations section of our corporate website after the meeting. There are no stockholder questions to be addressed at today's meeting. There being no further business to come before the meeting, the 2025 Annual Meeting of Stockholders of Phathom Pharmaceuticals is now adjourned. Thank you all for joining us today. The meeting has now concluded. Thank you for joining. You may disconnect.